[1]刘雨婷,冯国栋,席 玮,等.晚期胃癌动脉灌注化疗转化治疗的长期随访观察[J].介入放射学杂志,2026,(08):928-932.[doi:10.3969/j.issn.1008-794X.2026.08.017]
　LIU Yuting,FENG Guodong,XI Wei,et al.Long-term follow-up observation of conversion therapy using arterial infusion chemotherapy for advanced gastric cancer[J].J Intervent Med,2026,(08):928-932.[doi:10.3969/j.issn.1008-794X.2026.08.017]
点击复制

晚期胃癌动脉灌注化疗转化治疗的长期随访观察()

PDF下载中关闭

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2026年08
页码:
928-932
栏目:
临床研究
出版日期:
2026-08-12

文章信息/Info

Title:
Long-term follow-up observation of conversion therapy using arterial infusion chemotherapy for advanced gastric cancer
文章编号:
1008-794X(2026)-008-0928-05
作者:
刘雨婷;  冯国栋;  席 玮;  邱佳美;  张佳琪;  史厚辉;  华嘉科;  朱晓姝;  彭伟力;  高 杨;  王万胜;  陈 骏
310014 浙江杭州 浙江省人民医院(附属人民医院)杭州医学院,介入医学科,杭州师范大学第二临床医学院(浙江省人民医院)(刘雨婷); 复旦大学附属闵行医院放射科(冯国栋); 江苏省肿瘤医院(南京医科大学附属肿瘤医院)介入科(席 玮); 浙江省人民医院(附属人民医院),杭州医学院,肿瘤中心介入医学科(邱佳美,张佳琪,史厚辉,华嘉科,朱晓姝,彭伟力,高 杨,王万胜,陈 骏)
Author(s):
LIU Yuting; FENG Guodong; XI Wei; QIU Jiamei; ZHANG Jiaqi; SHI Houhui; HUA Jiake; ZHU Xiaoshu; PENG Weili; GAO Yang; WANG Wansheng; CHEN Jun.
Department of Interventional Medicine,Zhejiang Provincial People's Hospital,Hangzhou Medical College,Second Clinical Medical College of Hangzhou Normal University(Zhejiang Provincial People's Hospital),Hangzhou,Zhejiang Province 310014,China
关键词:
局部动脉灌注化疗;  局部晚期胃癌;  转化治疗
分类号:
R735.3
DOI:
10.3969/j.issn.1008-794X.2026.08.017
文献标志码:
B
摘要:
目的 探讨局部动脉灌注化疗(regional arterial infusion chemotherapy,RAIC)在局部晚期胃癌(locally advanced gastric cancer,LAGC)转化治疗中的价值。方法 回顾性分析2015—2017年江苏省肿瘤医院收治的17例多学科会诊(multi-disciplinary treatment,MDT)讨论评估为难以达到R0切除的LAGC行RAIC病例,其中8例(Ⅲa期1例,Ⅲc期7例)经过2～3次超选择性RAIC后,再次MDT评估认为有R0切除机会而择期行外科手术切除肿瘤。RAIC用药包括奥沙利铂 、依托泊苷和表柔比星。以动态增强CT及术后病理为依据,统计学分析化疗前后T分期和N分期的降期,病理学完全缓解率,1、3、5年总生存期。结果 RAIC转化治疗后,8例肿瘤缩小达到T分期降期,化疗前cT4a 3例、cT4b 5例,化疗后ypT0 2例、ypT1 2例、ypT2 4例; 其中5例转移的淋巴结缩小达到N分期降期,化疗前cN3 6例、cN2 1例、cN1 1例,化疗后ypN0 5例、ypN3 3例; 2例患者达到病理完全缓解。治疗期间及治疗后未见明显不良事件和围手术期并发症。1、3、5年生存率分别为100%、75%、50%,截至2025年6月11日仍有3例存活,最长存活时间达114个月。结论 RAIC可以作为LAGC的转化治疗方法,为患者提供长期生存获益的机会。

参考文献/References:

[1] Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71:209-249.
[2]Thrift AP,Wenker TN,El-Serag HB.Global burden of gastric cancer:epidemiological trends,risk factors,screening and prevention[J].Nat Rev Clin Oncol,2023,20:338-349.
[3]He YX,Wang YD,Luan FJ,et al.Chinese and global burdens of gastric cancer from 1990 to 2019[J].Cancer Med,2021,10:3461-3473.
[4]Al-Batran SE,Hofheinz RD,Pauligk C,et al.Histopathological regression after neoadjuvant docetaxel,oxaliplatin,fluorouracil,and leucovorin versus epirubicin,cisplatin,and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma(FLOT4-AIO):results from the phase 2 part of a multicentre,open-label,randomised phase 2/3 trial[J].Lancet Oncol,2016,17:1697-1708.
[5]Yu JR,Gao Y,Chen L,et al.Effect of S-1 plus oxaliplatin compared with fluorouracil,leucovorin plus oxaliplatin as perioperative chemotherapy for locally advanced,resectable gastric cancer:a randomized clinical trial[J].JAMA Netw Open,2022,5:e220426.
[6]Al-Batran SE,Homann N,Pauligk C,et al.Perioperative chemotherapy with fluorouracil plus leucovorin,oxaliplatin,and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced,resectable gastric or gastro-oesophageal junction adenocarcinoma(FLOT4):a randomised,phase 2/3 trial[J].Lancet,2019,393:1948-1957.
[7]Solaini L,Ministrini S,Bencivenga M,et al.Conversion gastrectomy for stage Ⅳ unresectable gastric cancer:a GIRCG retrospective cohort study[J].Gastric Cancer,2019,22:1285-1293.
[8]相小松,郭飞龙,苏钰,等.以动脉灌注化疗为基础术前治疗中晚期胃癌的单中心真实世界研究[J].中华肿瘤杂志,2025,47:183-192.
Xiang XS,Guo FL,Su Y,et al.Efficacy and prognosis of preoperative treatment based on arterial infusion chemotherapy in patients with advanced gastric cancer:a real-world study[J].Zhonghua Zhong Liu Za Zhi,2025,47:183-192.
[9]Ranieri G,Laforgia M,Nardulli P,et al.Oxaliplatin-based intra-arterial chemotherapy in colo-rectal cancer liver metastases:a review from pharmacology to clinical application[J].Cancers,2019,11:141.
[10]Cao YJ,Yu DD,Wu Y,et al.Regional intra-arterial vs.systemic chemotherapy for the treatment of advanced pancreatic cancer:a systematic review and meta-analysis[J].Front Oncol,2024,14:1197424.
[11]宋 杰,王黎洲,李 兴,等.中晚期胃癌行介入灌注化疗栓塞术的疗效评估[J].介入放射学杂志,2014,23:996-1000.
Song J,Wang LZ,Li X,et al.Evaluation of therapeutic effect of interventional perfusion chemoembolization in treating advanced gastric cancers[J].J Interv Radiol,2014,23:996-1000.
[12]朱明德,张子敬,季洪胜,等.进展期胃癌介入治疗疗效分析[J].介入放射学杂志,2008,17:136-139.
Zhu MD,Zhang ZJ,Ji HS,et al.Analysis of interventional therapy for progressing stage gastric cancer[J].J Interv Radiol,2008,17:136-139.
[13]中国抗癌协会肿瘤介入专家委员会.经导管动脉灌注化疗药物应用原则:中国肿瘤介入专家共识[J].介入放射学杂志,2017,26:963-970.
Tumor Intervention Expert Committee of Chinese AntiCancer Association.Chinese tumor intervention expert consensus on the application principles of transcatheter arterial infusion chemotherapy[J].J Interv Radiol,2017,26:963-970.
[14]Sato Y,Ohnuma H,Nobuoka T,et al.Conversion therapy for inoperable advanced gastric cancer patients by docetaxel,cisplatin,and S-1(DCS)chemotherapy:a multi-institutional retrospective study[J].Gastric Cancer,2017,20:517-526.
[15]Kohlbrenner R,Wu X,Nguyen HG,et al.Pharmacokinetic comparison of selective prostatic arterial and intravenous PSMA PET/CT radioligand infusions in primary prostatic adenocarcinoma[J].Radiology,2024,312:e232544.
[16]Sano T,Coit DG,Kim HH,et al.Proposal of a new stage grouping of gastric cancer for TNM classification:International Gastric Cancer Association staging project[J].Gastric Cancer,2017,20:217-225.
(收稿日期:2025-06-11)
(本文编辑:元 禾)

备注/Memo

备注/Memo:
基金项目: 江苏省2017年高层次卫生人才“六个一工程”拔尖人才科研项目(LGY2017087); 浙江省医药卫生科技计划(2025KY561)
通信作者: 陈 骏 E-mail:chenjun@hmc.edu.cn
更新日期/Last Update: 2026-08-25